Recommendations for Contraception in Women with Gynecologic Cancer: From Diagnosis to Post-Treatment
DOI:
https://doi.org/10.20344/amp.22396Keywords:
Contraception, Contraceptives, Oral, Genital Neoplasms, Female, Intrauterine DevicesAbstract
The incidence of gynecologic cancer in women of reproductive age is increasing, as is the trend towards fertility-sparing treatments, highlighting the importance of safe and effective contraceptive counseling. Selecting a contraceptive method requires careful consideration of the tumor’s histological subtype, its hormonal expression, and the timing of counseling within the cancer care continuum (diagnosis, treatment, and post-treatment phases). The Portuguese Society of Contraception and the Section of Gynecologic Oncology of the Portuguese Gynecological Society present recommendations about contraception in women with gynecologic cancer who have undergone fertility-sparing treatments, from diagnosis to the end of the reproductive age.
Downloads
References
Registo Oncológico Nacional. Registo oncológico nacional de todos os tumores na população residente em Portugal, em 2020. Porto: Instituto Português de Oncologia do Porto Francisco Gentil; 2023.
Oonk MH, Planchamp F, Baldwin P, Mahner S, Mirza MR, Fischerová D, et al. European society of gynaecological oncology guidelines for the management of patients with vulvar cancer - update 2023. Int J Gynecol Cancer. 2023;33:1023-43. DOI: https://doi.org/10.1136/ijgc-2023-004486
Nout RA, Calaminus G, Planchamp F, Chargari C, Lax S, Martelli H, et al. ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer. Int J Gynecol Cancer. 2023;33:1185-202. DOI: https://doi.org/10.1136/ijgc-2023-004695
Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - update 2023. Virchows Arch. 2023;482:935-66. DOI: https://doi.org/10.1007/s00428-023-03552-3
Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, et al. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023;2023:hoac057. DOI: https://doi.org/10.1093/hropen/hoac057
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30:672-705. DOI: https://doi.org/10.1093/annonc/mdz062
Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:Siv1-iv18. 8. Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. Int J Gynaecol Obstet. 2021;155:S7-18. DOI: https://doi.org/10.1093/annonc/mdy001
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021;155:S19-27. DOI: https://doi.org/10.1002/ijgo.13867
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155:S28-44. DOI: https://doi.org/10.1002/ijgo.13865
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155:S61-85. DOI: https://doi.org/10.1002/ijgo.13878
Sociedade Portuguesa de Ginecologia, Secção de Ginecologia Oncológica. Cancro ginecológico. Consensos nacionais 2020 [consultado 2024 dez 06]. Disponível em: https://spginecologia.pt/wp-content/uploads/2020/01/Brochuradig_ConsensosNacionais_23_310123-002.cleaned.pdf.
Genazzani AR, Fidecicchi T, Arduini D, Giannini A, Simoncini T. Hormonal and natural contraceptives: a review on efficacy and risks of different methods for an informed choice. Gynecol Endocrinol. 2023;39:2247093. DOI: https://doi.org/10.1080/09513590.2023.2247093
Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care. 2010;15:S19-31. DOI: https://doi.org/10.3109/13625187.2010.532999
World Health Organization. Medical eligibility criteria for contraceptive use. Geneva: WHO; 2015.
Dominick SA, McLean MR, Whitcomb BW, Gorman JR, Mersereau JE, Bouknight JM, et al. Contraceptive Practices among female cancer survivors of reproductive age. Obstet Gynecol. 2015;126:498-507. DOI: https://doi.org/10.1097/AOG.0000000000000963
Hadnott TN, Stark SS, Medica A, Dietz AC, Martinez ME, Whitcomb BW, et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019;111:763-71. DOI: https://doi.org/10.1016/j.fertnstert.2018.12.016
Harris ML, Feyissa TR, Bowden NA, Gemzell-Danielsson K, Loxton D. Contraceptive use and contraceptive counselling interventions for women of reproductive age with cancer: a systematic review and meta-analysis. BMC Med. 2022;20:489. DOI: https://doi.org/10.1186/s12916-022-02690-w
Massarotti C, Lo Monaco L, Scaruffi P, Sozzi F, Remorgida V, Cagnacci A, et al. Contraception in cancer survivors: insights from oncofertility follow-up visits. Gynecol Endocrinol. 2021;37:166-70. DOI: https://doi.org/10.1080/09513590.2020.1810658
Medica AC, Stark SS, Hadnott TN, Dietz AC, Romero SAD, Natarajan L, et al. Use of emergency contraception among female young adult cancer survivors. Fertil Steril. 2018;109:1114-20.e1. DOI: https://doi.org/10.1016/j.fertnstert.2018.02.136
Sociedade Portuguesa da Contraceção. Consenso sobre contraceção 2020 [consultado 2024 dez 10]. Disponível em: https://spginecologia.pt/wpcontent/ uploads/2021/07/spg-consenso-sobre-contracepcao-2020.pdf.
Nguyen AT, Curtis KM, Tepper NK, Kortsmit K, Brittain AW, Snyder EM, et al. U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep. 2024;73:1-126. DOI: https://doi.org/10.15585/mmwr.rr7304a1
Gompel A, Ramirez I, Bitzer J. Contraception in cancer survivors - an expert review part I. Breast and gynaecological cancers. Eur J Contracept Reprod Health Care. 2019;24:167-74. DOI: https://doi.org/10.1080/13625187.2019.1602721
Zapata LB, Whiteman MK, Marchbanks PA, Curtis KM. Intrauterine device use among women with ovarian cancer: a systematic review. Contraception. 2010;82:38-40. DOI: https://doi.org/10.1016/j.contraception.2010.02.013
Ayhan A, Fagotti A, Gultekin M, Pakiz M, Querleu D, Reed N, Taskıran C, editors.Textbook of gynaecological oncology. Platinum edition. Ankara: Güneş Publishing; 2023.
Donohoe F, O’Meara Y, Roberts A, Comerford L, Kelly CM, Walshe JM, et al. Using menopausal hormone therapy after a cancer diagnosis in Ireland. Ir J Med Sci. 2023;192:45-55. DOI: https://doi.org/10.1007/s11845-022-02947-6
Dika E, Patrizi A, Lambertini M, Manuelpillai N, Fiorentino M, Altimari A, et al. Estrogen receptors and melanoma: a review. Cells. 2019;8:1463. DOI: https://doi.org/10.3390/cells8111463
World Health Organization. WHO classification of tumours editorial board. Female genital tumors: WHO Classification of Tumours, 5th Edition, Volume 4. Lyon: International Agency for Research on Cancer; 2020.
Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010;30:1341-5.
Richardson A, Watson L, Persic M, Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post Reprod Health. 2021;27:167-73. DOI: https://doi.org/10.1177/20533691211028518
Lee SH, Cho YJ, Cho KJ, Ko MH, Jung SY, Chon SJ, et al. Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. Obstet Gynecol Sci. 2018;61:584-9. DOI: https://doi.org/10.5468/ogs.2018.61.5.584
Motegi E, Hasegawa K, Kawai S, Kiuchi K, Kosaka N, Mochizuki Y, et al. Levonorgestrel-releasing intrauterine system placement for severe uterine cervical stenosis after conization: two case reports. J Med Case Rep. 2016;10:56. DOI: https://doi.org/10.1186/s13256-016-0831-9
Li X, Li J, Wu X. Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: a systematic review. Eur J Cancer. 2015;51:1751-9. DOI: https://doi.org/10.1016/j.ejca.2015.05.012
Nasu K, Narahara H. Management of severe cervical stenosis after conization by detention of nylon threads tied up to intrauterine contraceptive device. Arch Gynecol Obstet. 2010;281:887-9. DOI: https://doi.org/10.1007/s00404-009-1205-y
Novikova OV, Nosov VB, Panov VA, Novikova EG, Krasnopolskaya KV, Andreeva YY, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecol Oncol. 2021;161:152-9. DOI: https://doi.org/10.1016/j.ygyno.2021.01.001
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer. 2019;116:35-44. DOI: https://doi.org/10.1016/j.ejca.2019.04.018
Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128:371-6. DOI: https://doi.org/10.1016/j.ygyno.2012.10.013
National Comprehensive Cancer Network. NCCN guidelines version 2.2024. Gestational trophoblastic neoplasia 2024 [consultado 2024 dez 10]. Disponível em: https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf.
Hagey JM, Drury KE, Kaplan S, Davidson BA, Morse JE. Contraceptive use following gestational trophoblastic disease: a systematic review. Contraception. 2024;137:110488. DOI: https://doi.org/10.1016/j.contraception.2024.110488
Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecol Oncol. 2006;100:579-85. DOI: https://doi.org/10.1016/j.ygyno.2005.09.031
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
